August 2016 Volume 12, Issue 8
Volume 12, Issue 8 | August 2016
August 2016
In this Issue
Research & Development
Building a better way of cancer modeling
International collaboration plans to create new cancer cell culture models to accelerate researchReliable and robust
Probiodrug and Crossbeta create strategic partnership for Alzheimer’s disease biomarkersTwo for biopharmaceutical characterization
Thermo Fisher and NIBRT pursue analytical solutions designed to streamline workflows, quickly generate dataPossible explanation for lithium efficacy
Pharmacological success as a mood stabilizer poorly understoodNovel data confirm optimal drug-like properties of BiXAb antibodies
BiXAb ‘plug-and-play’ bispecific antibodies reportedly demonstrated excellent in-vitro properties and in-vivo activityDiscovery
Five Prime collaborates with University of Minnesota
The organizations are partnering to expand hematopoietic stem cell optionsInvestigating the disease connection
NIH research into Gaucher disease uncovers a molecule that could also treat Parkinson’sA fresh look at polycystic kidney disease
Virtual tissue technology helps Indiana University researchers find new drug targetProgress with proteins
TSRI teams report on work that could boost anticancer efforts and drug developmentSpecial Reports
Special Report on Stem Cells: Finding common ground
Gene-based and stem cell-based therapies look for synergiesQ&A
Q&A: A conversation on Coversin
Gur Roshwalb expands on the complement system and its treatment candidate for rare diseases triggered by complement dysregulationEditor's Focus
Life sciences and pharma in ‘black and white’
True representation of the population in clinical trials is something we aren't yet achieving, but we need to get closer to that goal even if we never do truly reach itCommentary
Moonshot for pediatric pharmacology
Children tend to get left out in the cold when it comes to clinical research, but they are an important population that deserves better consideration when it comes to developing therapeuticsMarket insight: The changing biopharma risk equation
MilliporeSigma in June announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks associated with the changing biopharma landscapePreclinical
Lupus drug moves forward
Dalazatide found to suppress cytokines associated with lupus nephritis in children and teensGetting ahead with GWAS
Research team uses new genomic testing technique to link mouse genes with behavioral traitsSilenc(ing) disease-driving genes is golden
Dicerna unveils new preclinical data for GalXC delivery of RNAi-based therapy in fight vs. chronic liver diseaseManaging mast cells with masitinib
AB Science tyrosine kinase inhibitor shows potential in mediating ALS progressionBusiness & Government Policy
A busy June for Teva
Pharma giant inks several agreements divesting assets in preparation for closing Allergan generics dealAligning drugs and diagnostics
FDA releases draft guidance to outline principles of codeveloping therapeutics and companion diagnosticsOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsBioTek Instruments embarks on major site expansion
July sees start of $4-million facility expansion to meet company’s growing manufacturing and design needsSamsung Bioepis a step closer to marketing Humira biosimilar in Europe
Marketing Authorization Application for SB5 adalimumab biosimilar candidate accepted for review by the EMADiagnostics
Bio-Techne acquires Advanced Cell Diagnostics
$250-million-plus deal marks Bio-Techne’s entry into the realm of genomicsNew information about kataegis offers hope
Genetic phenomenon proves to be a positive marker in breast cancerMammary marker
IVD test aids in breast cancer subtypingOwlstone Medical closes $7M investment to commercialize disease breathalyzer
Owlstone Medical Ltd. was recently spun out of parent company Owlstone Inc. to develop and commercialize a breathalyzer for use in clinical diagnostics and precision medicineContract Services
WuXi AppTec expands reach with Reaxys license
Company plans to leverage database for synthetic, medicinal chemistry researchCloud collaboration yields fruit
A multi-institution team devises new prodrug, points to PLA2 as an IBD targetCrown Bioscience strengthens immuno-oncology platform
Company announces the launch of the OmniScreen cell panel screening platformClinical Trials
A new RESORCE for cancer patients?
RESORCE study finds Stivarga could improve overall survival in liver cancerNovartis makes progress with SM
Study shows promise for patients with systemic mastocytosisCulture of clinical trial management
SCORR report explains challenges and expectations of project managementA new tactic for treating T1D
Sernova receives funding from JDRF to advance its diabetes cell therapy to a clinical trialIn with ZGN-1061, out with beloranib
Zafgen shifts focus to second-gen MetAP2 inhibitor in wake of troubles around PWS candidateEsperion provides update for bempedoic acid
Esperion Therapeutics Inc. recently provided updates on the bempedoic acid (ETC-1002) clinical development program and regulatory plans
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
The unsung tools behind analytical testing success
Learn how fundamental laboratory tools like pipettes and balances support analytical precision.
Improving ALS research with pluripotent stem cell-derived models
Discover new advancements in modeling amyotrophic lateral sclerosis.
Automating 3D cell selection
Discover precise automated tools for organoid and spheroid handling.
